Febrile Neutropenia - Market Insight, Epidemiology and Market Forecast - 2027

Febrile Neutropenia - Market Insight, Epidemiology and Market Forecast - 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

100

Choose License

Final Price

DelveInsight's "Febrile Neutropenia - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Febrile Neutropenia epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Febrile Neutropenia Understanding and Treatment Algorithm
The market report provides the overview of the Febrile Neutropenia by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Febrile Neutropenia Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Febrile Neutropenia in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Febrile Neutropenia Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Febrile Neutropenia Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Febrile Neutropenia market.

Febrile Neutropenia Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Febrile Neutropenia Report Insights
• Patient Population in Febrile Neutropenia
• Therapeutic Approaches in Febrile Neutropenia
• Febrile Neutropenia Pipeline Analysis
• Febrile Neutropenia Market Size and Trends
• Febrile Neutropenia Market Opportunities
• Impact of upcoming Therapies in Febrile Neutropenia

Febrile Neutropenia Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Febrile Neutropenia Report Assessment
• Current Treatment Practices in Febrile Neutropenia
• Unmet Needs in Febrile Neutropenia
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Febrile Neutropenia market
• Organize sales and marketing efforts by identifying the best opportunities for Febrile Neutropenia market
• To understand the future market competition in the Febrile Neutropenia market.
1. Report Introduction
2. Febrile Neutropenia Market Overview at a Glance
2.1. Market Share Distribution of Febrile Neutropenia in 2017
2.2. Market Share Distribution of Febrile Neutropenia in 2027
3. Disease Background and Overview: Febrile Neutropenia
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Febrile Neutropenia in 7MM
4.3. Total Prevalent Patient Population of Febrile Neutropenia in 7MM – By Countries
5. Epidemiology of Febrile Neutropenia by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.1.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.1.4. Sex- Specific Cases of the Febrile Neutropenia *
5.1.5. Diagnosed Cases of the Febrile Neutropenia
5.1.6. Treatable Cases of the Febrile Neutropenia
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.4.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.4.4. Sex- Specific Cases of the Febrile Neutropenia *
5.4.5. Diagnosed Cases of the Febrile Neutropenia
5.4.6. Treatable Cases of the Febrile Neutropenia
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.5.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.5.4. Sex- Specific Cases of the Febrile Neutropenia *
5.5.5. Diagnosed Cases of the Febrile Neutropenia
5.5.6. Treatable Cases of the Febrile Neutropenia
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.6.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.6.4. Sex- Specific Cases of the Febrile Neutropenia *
5.6.5. Diagnosed Cases of the Febrile Neutropenia
5.6.6. Treatable Cases of the Febrile Neutropenia
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.7.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.7.4. Sex- Specific Cases of the Febrile Neutropenia *
5.7.5. Diagnosed Cases of the Febrile Neutropenia
5.7.6. Treatable Cases of the Febrile Neutropenia
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.8.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.8.4. Sex- Specific Cases of the Febrile Neutropenia *
5.8.5. Diagnosed Cases of the Febrile Neutropenia
5.8.6. Treatable Cases of the Febrile Neutropenia
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Febrile Neutropenia
5.9.3. Sub-Type Specific cases of the Febrile Neutropenia *
5.9.4. Sex- Specific Cases of the Febrile Neutropenia *
5.9.5. Diagnosed Cases of the Febrile Neutropenia
5.9.6. Treatable Cases of the Febrile Neutropenia
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Febrile Neutropenia
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Febrile Neutropenia
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Febrile Neutropenia : 7MM Market Analysis
12.1. 7MM Market Size of Febrile Neutropenia
12.2. 7MM Percentage Share of drugs marketed for Febrile Neutropenia
12.3. 7MM Market Sales of Febrile Neutropenia by Products
13. Febrile Neutropenia : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Febrile Neutropenia in United States
13.1.2. Percentage Share of drugs marketed for Febrile Neutropenia in United States
13.1.3. Market Sales of Febrile Neutropenia by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Febrile Neutropenia in Germany
13.2.1.2. Percentage Share of drugs marketed for Febrile Neutropenia in Germany
13.2.1.3. Market Sales of Febrile Neutropenia by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Febrile Neutropenia in France
13.2.2.2. Percentage Share of drugs marketed for Febrile Neutropenia in France
13.2.2.3. Market Sales of Febrile Neutropenia by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Febrile Neutropenia in Italy
13.2.3.2. Percentage Share of drugs marketed for Febrile Neutropenia in Italy
13.2.3.3. Market Sales of Febrile Neutropenia by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Febrile Neutropenia in Spain
13.2.4.2. Percentage Share of drugs marketed for Febrile Neutropenia in Spain
13.2.4.3. Market Sales of Febrile Neutropenia by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Febrile Neutropenia in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Febrile Neutropenia in United Kingdom
13.2.5.3. Market Sales of Febrile Neutropenia by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Febrile Neutropenia in Japan
13.3.2. Percentage Share of drugs marketed for Febrile Neutropenia in Japan
13.3.3. Market Sales of Febrile Neutropenia by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Febrile Neutropenia in 7MM
Table 2: Total Prevalent/Incident Cases of the Febrile Neutropenia in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Febrile Neutropenia in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Febrile Neutropenia in United States (2016-2027)
Table 5: Sex- Specific Cases of the Febrile Neutropenia in United States (2016-2027)
Table 6: Diagnosed Cases of the Febrile Neutropenia in United States (2016-2027)
Table 7: Treatable Cases of the Febrile Neutropenia in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Febrile Neutropenia in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Febrile Neutropenia in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Febrile Neutropenia in Germany (2016-2027)
Table 11: Diagnosed Cases of the Febrile Neutropenia in Germany (2016-2027)
Table 12: Treatable Cases of the Febrile Neutropenia in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Febrile Neutropenia in France (2016-2027)
Table 14: Sub-Type Specific cases of the Febrile Neutropenia in France (2016-2027)
Table 15: Sex- Specific Cases of the Febrile Neutropenia in France (2016-2027)
Table 16: Diagnosed Cases of the Febrile Neutropenia in France (2016-2027)
Table 17: Treatable Cases of the Febrile Neutropenia in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Febrile Neutropenia in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Febrile Neutropenia in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Febrile Neutropenia in Italy (2016-2027)
Table 21: Diagnosed Cases of the Febrile Neutropenia in Italy (2016-2027)
Table 22: Treatable Cases of the Febrile Neutropenia in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Febrile Neutropenia in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Febrile Neutropenia in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Febrile Neutropenia in Spain (2016-2027)
Table 26: Diagnosed Cases of the Febrile Neutropenia in Spain (2016-2027)
Table 27: Treatable Cases of the Febrile Neutropenia in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Febrile Neutropenia in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Febrile Neutropenia in UK (2016-2027)
Table 30: Sex- Specific Cases of the Febrile Neutropenia in UK (2016-2027)
Table 31: Diagnosed Cases of the Febrile Neutropenia in UK (2016-2027)
Table 32: Treatable Cases of the Febrile Neutropenia in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Febrile Neutropenia in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Febrile Neutropenia in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Febrile Neutropenia in Japan (2016-2027)
Table 36: Diagnosed Cases of the Febrile Neutropenia in Japan (2016-2027)
Table 37: Treatable Cases of the Febrile Neutropenia in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Febrile Neutropenia in USD MM (2016-2027)
Table 42:7MM- Market Share Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Febrile Neutropenia in USD MM (2016-2027)
Table 45: United States-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Febrile Neutropenia in USD MM (2016-2027)
Table 48: Germany-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Febrile Neutropenia in USD MM (2016-2027)
Table 51: France-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Febrile Neutropenia in USD MM (2016-2027)
Table 54: Italy-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Febrile Neutropenia in USD MM (2016-2027)
Table 57: Spain-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Febrile Neutropenia in USD MM (2016-2027)
Table 60:UK-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Febrile Neutropenia in USD MM (2016-2027)
Table 63: Japan-Market Share Febrile Neutropenia by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Febrile Neutropenia by Therapies in USD MM (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us